Levophacetoperane
From Wikipedia, the free encyclopedia
(Redirected from Phacetoperane)
Stimulant drugTemplate:SHORTDESC:Stimulant drug
Pharmaceutical compoundTemplate:SHORTDESC:Pharmaceutical compound
| Clinical data | |
|---|---|
| Routes of administration | Oral |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| E number | {{#property:P628}} |
| CompTox Dashboard (EPA) |
|
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 29: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C14H19NO2 |
| Molar mass | 233.311 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Levophacetoperane (Lidépran, Phacétoperane) is a psychostimulant developed by Rhône-Poulenc in the 1950s.[2] The drug has been used as an antidepressant and anorectic.[3][4] It is the reverse ester of methylphenidate. Phacetoperane and levophacetoperane have been used as wakefulness-promoting agents in the treatment of narcolepsy.[5]
See also
[edit | edit source]References
[edit | edit source]- ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
- ^ US 2928835, Marie JN, Michel JR, "New esters", published Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value)., assigned to Rhône-Poulenc
- ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
- ^ US 20150038533, Konofal E, Figadere B, "Phacetoperane for the treatment of attention-deficit hyperactivity disorder", published Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value)., assigned to Assistance Publique – Hôpitaux de Paris
- ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
| |||||||||||||||||||||
| |||||||||||||||||||||
| |||||||||||||||||||||
| |||||||||||||||||||||
| |||||||||||||||||||||
| DATTooltip Dopamine transporter (DRIsTooltip Dopamine reuptake inhibitors) |
| ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NETTooltip Norepinephrine transporter (NRIsTooltip Norepinephrine reuptake inhibitors) |
| ||||||||||||||
| SERTTooltip Serotonin transporter (SRIsTooltip Serotonin reuptake inhibitors) |
| ||||||||||||||
| VMATsTooltip Vesicular monoamine transporters | |||||||||||||||
| Others |
| ||||||||||||||
This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
Hidden categories:
- Pages with script errors
- Articles with short description
- Drugs with non-standard legal status
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Drugboxes which contain changes to watched fields
- All stub articles